Hypoparathyroidism

Endocrinology
9
Pipeline Programs
5
Companies
20
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
3100%
+ 9 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
1
1
rhPTHPhase 45 trials
NPSP558Phase 34 trials
Active Trials
NCT01455181Completed24Est. Apr 2012
NCT01297309Completed51Est. Jun 2018
NCT01268098Completed42Est. Nov 2011
+6 more trials
Ascendis Pharma
Ascendis PharmaCA - Palo Alto
6 programs
1
2
Palopegteriparatide Experimental ArmPhase 31 trial
TransCon PTHPhase 31 trial
TransCon PTHPhase 21 trial
PalopegteriparatideN/APeptide1 trial
PalopegteriparatideN/APeptide1 trial
+1 more programs
Active Trials
NCT07345494Recruiting50Est. Jan 2036
NCT07264634Not Yet Recruiting10Est. Jan 2028
NCT05654701Approved For Marketing
+3 more trials
VISEN Pharmaceuticals
VISEN PharmaceuticalsChina - Shanghai
1 program
1
TransCon PTHPhase 31 trial
Active Trials
NCT05387070CompletedEst. Jan 2026
MBX Biosciences
MBX BiosciencesCARMEL, IN
2 programs
2
400 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 21 trial
MBX 2109Phase 21 trial
Active Trials
NCT06531941Active Not Recruiting60Est. May 2027
NCT06465108Completed64Est. Jun 2025
CP
Chugai PharmaJapan - Tokyo
1 program
1
PCO371Phase 11 trial
Active Trials
NCT04209179Terminated5Est. May 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedarhPTH
Ascendis PharmaPalopegteriparatide Experimental Arm
TakedarhPTH
VISEN PharmaceuticalsTransCon PTH
Ascendis PharmaTransCon PTH
TakedarhPTH
TakedaNPSP558
TakedaNPSP558
TakedaNPSP558
TakedaNPSP558
MBX Biosciences400 µg of MBX 2109 once-weekly by subcutaneous injection
MBX BiosciencesMBX 2109
Ascendis PharmaTransCon PTH
TakedarhPTH
Chugai PharmaPCO371

Showing 15 of 19 trials with date data

Clinical Trials (20)

Total enrollment: 878 patients across 20 trials

NCT03324880TakedarhPTH

A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Start: Jan 2018Est. completion: May 202293 patients
Phase 4Completed
NCT07081997Ascendis PharmaPalopegteriparatide Experimental Arm

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Start: Apr 2026Est. completion: Jun 202836 patients
Phase 3Not Yet Recruiting
NCT03878953TakedarhPTH

A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

Start: Aug 2022Est. completion: May 20230
Phase 3Withdrawn
NCT05387070VISEN PharmaceuticalsTransCon PTH

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Start: Jul 2021Est. completion: Jan 2026
Phase 3Completed
NCT04701203Ascendis PharmaTransCon PTH

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Start: Feb 2021Est. completion: Jan 202584 patients
Phase 3Completed
NCT03364738TakedarhPTH

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

Start: Sep 2018Est. completion: Apr 202022 patients
Phase 3Terminated
NCT01455181TakedaNPSP558

A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary

Start: Aug 2011Est. completion: Apr 201224 patients
Phase 3Completed
NCT01297309TakedaNPSP558

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Start: Apr 2011Est. completion: Jun 201851 patients
Phase 3Completed
NCT01268098TakedaNPSP558

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Start: Feb 2011Est. completion: Nov 201142 patients
Phase 3Completed
NCT00732615TakedaNPSP558

Use of NPSP558 in the Treatment of Hypoparathyroidism

Start: Dec 2008Est. completion: Sep 2011124 patients
Phase 3Completed
NCT06531941MBX Biosciences400 µg of MBX 2109 once-weekly by subcutaneous injection

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Start: Oct 2024Est. completion: May 202760 patients
Phase 2Active Not Recruiting
NCT06465108MBX BiosciencesMBX 2109

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Start: Aug 2024Est. completion: Jun 202564 patients
Phase 2Completed
NCT04009291Ascendis PharmaTransCon PTH

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Start: Aug 2019Est. completion: Apr 202559 patients
Phase 2Completed
NCT05137730TakedarhPTH

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

Start: Nov 2021Est. completion: Apr 202296 patients
Phase 1Completed
NCT04209179Chugai PharmaPCO371

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

Start: Jul 2020Est. completion: May 20215 patients
Phase 1Terminated
NCT03150108TakedarhPTH

Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects

Start: May 2017Est. completion: Jun 201724 patients
Phase 1Completed
NCT02781844TakedarhPTH

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

Start: Apr 2017Est. completion: Mar 201934 patients
Phase 1Completed
NCT05654701Ascendis PharmaPalopegteriparatide

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

N/AApproved For Marketing
NCT07345494Ascendis PharmaPalopegteriparatide

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Start: Feb 2026Est. completion: Jan 203650 patients
N/ARecruiting
NCT07264634Ascendis PharmaPalopegteriparatide

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Start: Jan 2026Est. completion: Jan 202810 patients
N/ANot Yet Recruiting

Related Jobs in Endocrinology

Research Associate I/II - Biology

Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr

Associate Director, Clinical Operations

Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr

Associate Director/Director, Regulatory Affairs

Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr

Medical Science Liaison (rare diseases)

Amgen
Poland - Lódz
1mo ago

Senior/Executive Director, Analytical Development

Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr

Senior Clinical Scientist - Job ID: 1845

Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 878 patients
5 companies competing in this space

Related Indications

Acromegaly(67)Growth Hormone Deficiency(39)Growth Hormone Disorder(37)Hypogonadism(21)Secondary Hyperparathyroidism(13)Thyroid Eye Disease(11)Adult Growth Hormone Deficiency(10)Hypothyroidism(9)Cushing's Syndrome(9)Growth Hormone Deficiency in Children(5)